CHP
PBE icon

Cable Hill Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Cable Hill Partners’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-600
Closed -$33K – 524
2019
Q1 		$33K Buy
+600
New +$31.7K 0.01% 303

Other funds holding PBE

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cable Hill Partners's PBE Position: Q2 2019 in Review

Cable Hill Partners sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2019, closing a stake of 600 shares — an estimated $33K sold.

Cable Hill Partners first reported a position in PBE in Q1 2019 and held it in 1 quarter. The position peaked at $33K in Q1 2019. 81 funds tracked by Wall St. Rank hold PBE as of Q2 2019.

  • Cable Hill Partners reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 600 Invesco Biotechnology & Genome ETF shares in Q2 2019, an estimated $33K.
  • Cable Hill Partners first reported a position in Invesco Biotechnology & Genome ETF in Q1 2019 and held it in 1 quarter.
  • Cable Hill Partners's Invesco Biotechnology & Genome ETF position peaked at $33K in Q1 2019.
  • 81 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.